Het Academisch Ziekenhuis van Luik is een ziekenhuis in de Belgische stad Luik. Het ziekenhuis is een academisch ziekenhuis verbonden aan de Université de Liège. Naast de hoofdcampus in Sart-Tilman waar 625 bedden zijn erkend heeft het ziekenhuis ook campussen of afdelingen in Chênée, Esneux en Fraiture-en-Condroz.

During the past decade, CHU Sart-Tilman conducted 134 clinical trials. In the 10-year time frame, 134 clinical trials started and 76 clinical trials were completed, i.e. on average, 56.7% percent of trials that started reached the finish line to date. In the past 5 years, 45 clinical trials started and 45 clinical trials were completed. i.e. 100% of trials that started reached the finish line.

Out of the total clinical trials conducted in "CHU Sart-Tilman" #1 sponsor was "Hoffmann-La Roche" with 32 trials, followed by "European Organisation for Research and Treatment of Cancer - EORTC" with 27 trials sponsored, "Janssen Research & Development, LLC" with 13 trials sponsored, "ETOP IBCSG Partners Foundation" with 9 trials sponsored and "Amgen" with 9 trials sponsored. Other sponsors include 165 different institutions and companies that sponsored additional 106 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "CHU Sart-Tilman" #1 collaborator was "Breast International Group" with 8 trials as a collaborator, "Merck KGaA, Darmstadt, Germany" with 8 trials as a collaborator, "Gruppo Italiano Malattie EMatologiche dell'Adulto" with 5 trials as a collaborator, "ETOP IBCSG Partners Foundation" with 4 trials as a collaborator and "Hoffmann-La Roche" with 4 trials as a collaborator. Other collaborators include 170 different institutions and companies that were collaborators in the rest 142 trials.

According to Clinical.Site data, the most researched conditions in "CHU Sart-Tilman" are "Breast Cancer" (27 trials), "Leukemia" (8 trials), "Colorectal Cancer" (7 trials), "Ovarian Cancer" (7 trials) and "Coronary Artery Disease" (6 trials). Many other conditions were trialed in "CHU Sart-Tilman" in a lesser frequency.

Most popular intervention types in "CHU Sart-Tilman" are "Drug" (200 trials), "Other" (27 trials), "Procedure" (21 trials), "Biological" (17 trials) and "Device" (17 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (38 trials), "Paclitaxel" (14 trials), "Cyclophosphamide" (9 trials), "Carboplatin" (8 trials) and "Atezolizumab" (7 trials). Other intervention names were less common.

The vast majority of trials in "CHU Sart-Tilman" are 209 trials for "All" genders, 36 trials for "Female" genders and 13 trials for "Male" genders.

Currently, there are NaN active trials in "CHU Sart-Tilman". undefined are not yet recruiting, 39 are recruiting, 40 are Active, not recruiting, and 1 are Enrolling by invitation. In total, there were 141 completed trials in CHU Sart-Tilman, 1 suspended trials, and 26 terminated clinical trials to date.

Out of the total trials that were conducted in CHU Sart-Tilman, 19 "Phase 1" clinical trials were conducted, 69 "Phase 2" clinical trials and 119 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 10 trials, and there were also 20 trials that are defined as “Not Applicable".